Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

beta-thalassemia

- PMLiVE

Pfizer’s sickle cell disease therapy Oxbryta recommended by NICE for NHS use

About 4,000 people in England with the genetic blood disorder are expected to benefit from the decision

- PMLiVE

Sanofi/Sobi’s efanesoctocog alfa recommended by CHMP to treat haemophilia A

The rare genetic condition reduces production of factor VIII, an essential protein for blood clotting

- PMLiVE

Takeda’s fruquintinib recommended by CHMP for metastatic colorectal cancer

Approximately 520,000 new cases of colorectal cancer were diagnosed in Europe in 2020

- PMLiVE

J&J’s Rybrevant combination recommended by CHMP to treat advanced lung cancer

The fully-human EGFR-MET bispecific antibody has been recommended as a first-line treatment option

Biogen Idec building

Biogen’s tocilizumab biosimilar Tofidence recommended by CHMP to treat arthritis and COVID-19

The committee’s decision was supported by evidence demonstrating Tofidence’s similarity to Roche’s RoActemra

- PMLiVE

Vertex to expand autoimmune and inflammatory disease pipeline with $4.9bn Alpine acquisition

The company will gain rights to Alpine’s lead molecule, povetacicept, to treat IgA nephropathy

- PMLiVE

Pfizer’s antibiotic combination receives CHMP recommendation to treat multidrug-resistant infections

Antimicrobial resistance has been declared by WHO as one of the top ten threats to global public health

- PMLiVE

Pfizer/Astellas’ Xtandi receives CHMP recommendation to treat recurrent prostate cancer

For nine out of ten patients with nmHSPC with high-risk BCR, their condition will progress into a metastatic disease

- PMLiVE

Novo Nordisk’s Awiqli receives CHMP recommendation to treat diabetes in adults

The chronic disease is estimated to affect 415 million people worldwide

- PMLiVE

UCB’s Bimzelx recommended by CHMP to treat hidradenitis suppurativa in adults

The inflammatory skin disease affects an estimated 1% of the population in most studied countries

- PMLiVE

CHMP recommends Travere and CSL Vifor’s Filspari to treat rare kidney disease IgAN

The rare form of kidney disease is estimated to affect around 25 per million adults worldwide

- PMLiVE

BeiGene’s tislelizumab receives CHMP recommendation for non-small cell lung cancer

Lung cancer is the second most common type of cancer and the leading cause of cancer-related death globally

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links